Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
13
12
2022
medline:
2
2
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
Use of the direct oral anticoagulant rivaroxaban has strongly increased in Europe since its market approval for non-valvular atrial fibrillation in 2011. Patients characteristics of rivaroxaban initiators may have changed over time but this has not been investigated so far. We aimed to describe time trends of patient baseline characteristics among new rivaroxaban users with non-valvular atrial fibrillation from 2011 to 2016/17 in two European countries. We used data from Germany (German Pharmacoepidemiological Research Database) and the Netherlands (PHARMO Database Network). We included new rivaroxaban users with (i) a first dispensing between 2011 and 2016/17, (ii) ≥ 2 years of age, and (iii) a diagnosis of non-valvular atrial fibrillation and described their baseline medication and comorbidity prior to starting rivaroxaban stratified by year of inclusion. Overall, 130,652 new rivaroxaban users were included during the study period (Germany: N = 127,743, the Netherlands: N = 2909). The sex ratio and median age remained relatively stable over time. The proportion of patients without prior use of oral anticoagulants before initiation of rivaroxaban increased in both countries between 2011 and 2016/17 (Germany: from 51 to 76%, the Netherlands: from 57 to 85%). In Germany, we observed a relative decrease by 27% in the proportion of new rivaroxaban users with a history of ischemic stroke and by 18% in the proportion with a transient ischemic attack at baseline. No such a pattern was observed in the Netherlands. The proportion of patients with heart failure at baseline showed a three-fold increase in the Netherlands, while there was a relative decrease by 12% in Germany. Patient characteristics of new rivaroxaban users with non-valvular atrial fibrillation changed between 2011 and 2016/17, but changes differed between countries. These patterns have methodological implications. They have to be considered in the interpretation of observational studies comparing effectiveness and safety of oral anticoagulants, especially regarding potential bias due to unmeasured confounding.
Sections du résumé
BACKGROUND
BACKGROUND
Use of the direct oral anticoagulant rivaroxaban has strongly increased in Europe since its market approval for non-valvular atrial fibrillation in 2011. Patients characteristics of rivaroxaban initiators may have changed over time but this has not been investigated so far.
OBJECTIVE
OBJECTIVE
We aimed to describe time trends of patient baseline characteristics among new rivaroxaban users with non-valvular atrial fibrillation from 2011 to 2016/17 in two European countries.
METHODS
METHODS
We used data from Germany (German Pharmacoepidemiological Research Database) and the Netherlands (PHARMO Database Network). We included new rivaroxaban users with (i) a first dispensing between 2011 and 2016/17, (ii) ≥ 2 years of age, and (iii) a diagnosis of non-valvular atrial fibrillation and described their baseline medication and comorbidity prior to starting rivaroxaban stratified by year of inclusion.
RESULTS
RESULTS
Overall, 130,652 new rivaroxaban users were included during the study period (Germany: N = 127,743, the Netherlands: N = 2909). The sex ratio and median age remained relatively stable over time. The proportion of patients without prior use of oral anticoagulants before initiation of rivaroxaban increased in both countries between 2011 and 2016/17 (Germany: from 51 to 76%, the Netherlands: from 57 to 85%). In Germany, we observed a relative decrease by 27% in the proportion of new rivaroxaban users with a history of ischemic stroke and by 18% in the proportion with a transient ischemic attack at baseline. No such a pattern was observed in the Netherlands. The proportion of patients with heart failure at baseline showed a three-fold increase in the Netherlands, while there was a relative decrease by 12% in Germany.
CONCLUSIONS
CONCLUSIONS
Patient characteristics of new rivaroxaban users with non-valvular atrial fibrillation changed between 2011 and 2016/17, but changes differed between countries. These patterns have methodological implications. They have to be considered in the interpretation of observational studies comparing effectiveness and safety of oral anticoagulants, especially regarding potential bias due to unmeasured confounding.
Identifiants
pubmed: 36725812
doi: 10.1007/s40801-022-00350-2
pii: 10.1007/s40801-022-00350-2
pmc: PMC10232386
doi:
Types de publication
Journal Article
Langues
eng
Pagination
215-224Informations de copyright
© 2023. The Author(s).
Références
Open Heart. 2017 Sep 23;4(2):e000682
pubmed: 29018536
Br J Clin Pharmacol. 2021 Feb;87(2):632-643
pubmed: 32530052
BMC Med. 2020 Aug 27;18(1):254
pubmed: 32847578
Thromb Haemost. 2018 Mar;118(3):526-538
pubmed: 29359278
Clin Epidemiol. 2020 Apr 29;12:415-422
pubmed: 32425609
BMJ Open. 2014 May 15;4(5):e004587
pubmed: 24833682
Br J Clin Pharmacol. 2017 Sep;83(9):2096-2106
pubmed: 28390065
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Br J Clin Pharmacol. 2019 Nov;85(11):2524-2539
pubmed: 31318059
Eur Heart J. 2012 Nov;33(21):2719-47
pubmed: 22922413
Expert Opin Drug Saf. 2020 Nov;19(11):1513-1520
pubmed: 32700977
BMJ Open. 2018 Mar 30;8(3):e018180
pubmed: 29602837
Circulation. 2016 Apr 19;133(16):1540-7
pubmed: 26969761
J Am Coll Cardiol. 2014 Mar 11;63(9):891-900
pubmed: 24315894
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Heart. 2017 Feb 15;103(4):307-314
pubmed: 27647168
Am J Cardiol. 2018 Sep 1;122(5):785-792
pubmed: 30049460
Int J Clin Pract. 2022 Jan 31;2022:6707985
pubmed: 35685531
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724